Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: FASN inhibitors - Sagimet Biosciences

Next Previous
Drug Profile

Research programme: FASN inhibitors - Sagimet Biosciences

Alternative Names: TVB-3664

Latest Information Update: 23 May 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3-V Biosciences
  • Developer Sagimet Biosciences
  • Class Antineoplastics; Antivirals; Hepatoprotectants; Small molecules
  • Mechanism of Action Fatty acid synthetase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuroendocrine tumours
  • No development reported Cytomegalovirus infections; Hepatitis C; Herpes simplex virus infections; Non-alcoholic steatohepatitis; Parainfluenza virus infections; Respiratory syncytial virus infections; Solid tumours

Most Recent Events

  • 08 Apr 2022 Preclinical trials in Neuroendocrine tumours in USA (PO)
  • 08 Apr 2022 Pharmacodynamics data from a preclinical study in Neuroendocrine tumours presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
  • 28 Nov 2021 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top